30 closest matches · ranked by relevance
Obesity · Metabolic Syndrome
Primary: In Vivo Adipose Cell Formation (Adipogenesis) — -0.3; 1.8; -1.2; 2.1 percent
Body Fat Disorder
Primary: Safety of CoolScupting in the Submental Area — 4 incidence of device- and/or procedure AE
Subcutaneous Fat
Primary: Difference in Thickness of Subcutaneous Fat at Different Anatomic Sites on the Body — .56; .60; .83; 1.65 average fat measurement (cm)
Fat Reduction
Primary: Proportion of Pre-treatment Images Correctly Identified — 128 photos — p=<0.001
Central Abdominal Bulging
Primary: Percentage of Subjects Who Achieved a Composite P-GAPS1/CPnS2 Response — 37; 48 Participants — p=0.397
Body Fat Disorder
Primary: Percentage of Accurately Identified Pre-treatment Photos — 33; 23; 50; 23 photos
Morbid Obesity
Primary: Decrease in the Visceral Fat Layer Measured by Ultrasound a Day Before and a Year After Surgery. — 3.6; 7.1; 5.6 visceral fat reduction in centimeters
Body Fat Disorder
Primary: Proportion of Correctly Identified Photos by Blinded Reviewers — 28 photos
Body Fat
Primary: Number of Participants Who's Abdominal Tissue Showed Necrosis or Inflammatory Immune Cell Response — 10; 0 Participants
Obesity
Primary: Visceral Fat Volume With Automated Analysis — 994 cubic centimeters
Fat Disorder
Primary: Change in Fat Layer Thickness of the Treated Flank — -18.7; -22.6; -17.8; -17.5 percent fat layer change
Obesity · Type 2 Diabetes
Primary: Pancreatic and Liver Triglyceride (Fat) Content — 6.44; 2.08 percent
Body Fat Disorder
Primary: The Proportion of Subjects Who Have at Least a 1-grade Improvement on the Clinician Reported Submental Fat Rating Scale (CR-SMFRS) at the Final Follow-up Visit When…
Body Fat Disorder
Primary: Proportion of Accurately Identified Pre-Treatment Photos by a Panel of Blinded Independent Reviewers — 11 photos
Obesity · Type 2 Diabetes · Insulin Sensitivity
Primary: Insulin Sensitivity at 2 Years — 6.7; 6.6 glucose/kg body weight/min
Obesity
Primary: Change in Visceral and Subcutaneous Abdominal Adipose Tissue Over 6 Months — 57; 799; -111; 3634 mm^2 — p=0.70
Brown Adipose Tissue · Body Composition
Primary: Whole Body Fat Mass — 20.8 percentage of fat mass
Treatment of Adipose Tissue in the Thighs
Primary: Clinical Improvement in Thigh Circumference — -1.22; -0.59 centimeter
Fat Disorder
Primary: Change in Fat Thickness at Final Follow-up Compared to Baseline — -1.76 millimeters
Body Fat Disorder
Primary: The Number of Device and/or Procedure-Related Adverse Events — 12 device or procedure-related AEs
Body Fat Disorder
Primary: Percentage of Correctly Identified Pre-treatment Photos by a Panel of Blinded Independent Reviewers — 16; 15 photos
Body Fat Disorder
Primary: Safety of the Zeltiq CoolSculpting System in the Outer Thighs — 8; 0 events
Type2 Diabetes · Coronary Artery Disease
Primary: EAT Inflammation — 0.70; 1.4; 0.39; 0.25 ct (cycle threshold)
Central Obesity
Primary: Body Fat (kg) — 40.96; 40.12; 2.94; 4.26 kg
Excess Abdominal Fat
Primary: Change in Abdominal Fat Thickness Compared to Baseline as Measured by Ultrasound — -10.5 percentage change
Characteristics of Subcutaneous Tissue
Primary: Number of Participants With a Histologic Change in a Tissue Specimen That Was Injected With CCH — 2; 1; 1; 2 Participants
Abdominal Obesity · Growth Hormone Deficiency
Primary: Change in Visceral Adipose Tissue Volume — -16; 19 cm2
Abdominal Subcutaneous Fat
Primary: Waist Circumference Change — -2.03 Inches
Body Fat Disorder
Primary: Change in the Fat Layer of the Treated Area as Measured by Ultrasound The Change in Fat Layer Thickness in the Treated Outer Thigh — -0.25 cm
Reduction of Unwanted Fat
Primary: Percentage of Participants With Visible Improvement in Treated Area — 65.2; 82.8 percentage of participants